200 results on '"Paz, Keren"'
Search Results
2. RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients
3. Distinct SNARE Complexes Mediating Membrane Fusion in Golgi Transport Based on Combinatorial Specificity
4. Abstract 6657: Phase I trial of first-in-class anti-PVR mAb NTX1088: Restoration of DNAM1 expression as MOA for enhanced antitumor immunity
5. Data from KRAS Mutation Status Is Associated with Enhanced Dependency on Folate Metabolism Pathways in Non–Small Cell Lung Cancer Cells
6. Supplementary Table 2 from KRAS Mutation Status Is Associated with Enhanced Dependency on Folate Metabolism Pathways in Non–Small Cell Lung Cancer Cells
7. Supplementary Table 1 from KRAS Mutation Status Is Associated with Enhanced Dependency on Folate Metabolism Pathways in Non–Small Cell Lung Cancer Cells
8. Supplementary Table 3 from KRAS Mutation Status Is Associated with Enhanced Dependency on Folate Metabolism Pathways in Non–Small Cell Lung Cancer Cells
9. Data from Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3–MYC Interactions as a Target in Pancreatic Cancer
10. Figure S7 from Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3–MYC Interactions as a Target in Pancreatic Cancer
11. Supplementary Table 2 from Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment
12. Supplementary Table 1 from Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment
13. Table S1 from Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3–MYC Interactions as a Target in Pancreatic Cancer
14. Tables S1 and S3 from Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3–MYC Interactions as a Target in Pancreatic Cancer
15. Supplementary Methods from Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment
16. Supplementary Table 1 from The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors
17. Supplementary Figure 4 from The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors
18. Supplementary Figure 1 from The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors
19. Supplementary Figure 3 from The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors
20. Data from The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors
21. Supplementary Figure Legends from The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors
22. Supplementary Figure 5 from The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors
23. Supplementary Figure 2 from The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors
24. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line
25. 474 First-in-class anti-PVR mAb NTX1088 restores expression of DNAM1 and augments antitumor immunity
26. Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2 for Cancer Therapy
27. Abstract 5534: NTX-1088, a first-in-class anti-PVR mAb mediates DNAM1-dependent antitumor immunity
28. Abstract P075: NTX-1088, a potent first-in-class, anti-PVR mAb, restores expression and function of DNAM1 for optimal DNAM1-mediated antitumor immunity
29. Abstract P102: NTX-1088, A potent first-in-class, anti-PVR mAb, restores expression and function of DNAM1 for optimal DNAM1-mediated antitumor immunity
30. 254 NTX-1088, a potent anti-PVR Mab induces DNAM1-mediated antitumor immunity
31. Patient-derived xenografts for individualized care in advanced sarcoma
32. Transformation fingerprint: induced STAT3-C, v-Src and Ha-Ras cause small initial changes but similar established profiles in mRNA
33. Compartmental specificity of cellular membrane fusion encoded in SNARE proteins
34. Extracellular Matrix Proteins Modulate Endocytosis of the Insulin Receptor
35. Transactivation of ErbB2 and ErbB3 by Tumor Necrosis Factor-α and Anisomycin Leads to Impaired Insulin Signaling through Serine/Threonine Phosphorylation of IRS Proteins
36. Insulin Stimulates PKCζ-mediated Phosphorylation of Insulin Receptor Substrate-1 (IRS-1): A SELF-ATTENUATED MECHANISM TO NEGATIVELY REGULATE THE FUNCTION OF IRS PROTEINS
37. Withdrawal: Insulin stimulates PKCζ -mediated phosphorylation of insulin receptor substrate-1 (IRS-1): A self-attenuated mechanism to negatively regulate the function of IRS proteins.
38. Regulation of Cellular Heterogeneity and Rates of Symmetric and Asymmetric Divisions in Triple-Negative Breast Cancer
39. Phosphorylation of Insulin Receptor Substrate-1 (IRS-1) by Protein Kinase B Positively Regulates IRS-1 Function
40. Comparative mutational landscape analysis of patient-derived tumour xenografts
41. Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3–MYC Interactions as a Target in Pancreatic Cancer
42. MEK inhibitors block growth of lung tumours with mutations in ataxia–telangiectasia mutated
43. Abstract A40: The ImmunoGraftTM: A humanized mouse model for translational assessment of immunotherapy in solid tumors
44. Abstract B07: Screening of patient-derived carcinoma cells and animal models identifies transcription as target in pancreatic cancer.
45. Abstract A21: Accurate molecular fidelity of patient-derived xenograft (PDX) models to original human tumors and to The Cancer Genome Atlas (TCGA)
46. Abstract B40: Mouse clinical trials: integrating PDX models of sarcoma subtypes with genomics to replicate patient responses to cancer therapeutics
47. Abstract 3640: Validation of qBiomarker as an accurate and efficient mutation detection method in a comprehensive analysis of patient-derived tumor xenografts
48. Alveolar rhabdomyosarcoma: morphoproteomics and personalized tumor graft testing further define the biology of PAX3-FKHR(FOXO1) subtype and provide targeted therapeutic options
49. Abstract A77: Screening of conditionally reprogrammed patient-derived carcinoma cells identifies ERCC3-MYC interactions as a target in pancreatic cancer
50. Abstract A8: The ImmunoGraft: A humanized mouse model for translational assessment of immunotherapy in solid tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.